Adverse events3,395

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 3,395

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	Fatigue	General disorders	Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab	2	6
other	Fatigue	General disorders	Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab	6	7
other	Fatigue	General disorders	Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab	6	9
other	Fatigue	General disorders	Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab	14	18
other	Fatigue	General disorders	Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab	36	76
other	Fatigue	General disorders	Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab	29	53
other	Fatigue	General disorders	Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab	22	38
other	Oedema peripheral	General disorders	Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab	1	6
other	Oedema peripheral	General disorders	Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab	1	7
other	Oedema peripheral	General disorders	Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab	0	9
other	Oedema peripheral	General disorders	Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab	3	18
other	Oedema peripheral	General disorders	Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab	10	76
other	Oedema peripheral	General disorders	Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab	10	53
other	Oedema peripheral	General disorders	Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab	2	38
other	Pyrexia	General disorders	Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab	2	6
other	Pyrexia	General disorders	Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab	0	7
other	Pyrexia	General disorders	Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab	1	9
other	Pyrexia	General disorders	Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab	3	18
other	Pyrexia	General disorders	Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab	9	76
other	Pyrexia	General disorders	Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab	9	53

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02437136/events

API reference For AI assistants

Adverse events3,395

Sources 3

Read this list from software.